Metraipolis › archive › dc_331f6a8707b0

Efficacy outcomes between tarlatamab and real-world physicians' choice of therapies for previously treated extensive stage small cell lung cancer — Europe PMC PMID:40839303

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40839303
DOI
10.1093/oncolo/oyaf256
License (as archived)
solo-consultazione
Archived
2026-11-10T05:30:17.726Z
SHA-256 of the archived text
57c91736c04800c3ea57d4454a7702091dd60f856648ec348ef81ac1f3673e51
Stable URL of this page
https://metraipolis.com/documento/dc_331f6a8707b0

How to cite

Efficacy outcomes between tarlatamab and real-world physicians' choice of therapies for previously treated extensive stage small cell lung cancer — Europe PMC PMID:40839303 — Europe PMC (en), https://europepmc.org/article/MED/40839303 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_331f6a8707b0 (Metraipolis archive dc_331f6a8707b0, sha256 57c91736c04800c3ea57d4454a7702091dd60f856648ec348ef81ac1f3673e51)
BibTeX
@misc{dc331f6a8707b0,
  title = {Efficacy outcomes between tarlatamab and real-world physicians' choice of therapies for previously treated extensive stage small cell lung cancer — Europe PMC PMID:40839303},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40839303},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_331f6a8707b0; sha256 57c91736c04800c3ea57d4454a7702091dd60f856648ec348ef81ac1f3673e51},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40839303. Agents can read the archived copy with the MCP tool read_document.